Cleo Bertels, Iris Dirven, Manon Vounckx, Ivan Van Riet, Ann De Becker, Bart Neyns. "A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1)
                    <sup>+</sup>
                    /CD141 (BDCA-3)
                    <sup>+</sup>
                    myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e21514